A Phase IIa, Proof of Concept Study is to Determine the Degree of Mobilisation of CD34+ Cells Following Administration of POL6326 in Patients With Multiple Myeloma

Trial Profile

A Phase IIa, Proof of Concept Study is to Determine the Degree of Mobilisation of CD34+ Cells Following Administration of POL6326 in Patients With Multiple Myeloma

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2014

At a glance

  • Drugs Balixafortide (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors Polyphor
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Jun 2014 Last checked against ClinicalTrials.gov.
    • 22 Apr 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top